Search results
Results from the WOW.Com Content Network
Replication cycle of a coronavirus. The 5' and 3' ends of the genome have a cap and poly(A) tract, respectively.The viral envelope, obtained by budding through membranes of the endoplasmic reticulum (ER) or Golgi apparatus, invariably contains two virus-specified glycoprotein species, known as the spike (S) and membrane (M) proteins.
Transmission and life-cycle of SARS-CoV-2 causing COVID-19. Coronaviruses vary significantly in risk factor. Some can kill more than 30% of those infected, such as MERS-CoV, and some are relatively harmless, such as the common cold. [49] Coronaviruses can cause colds with major symptoms, such as fever, and a sore throat from swollen adenoids. [91]
SARS-CoV-2 is the seventh known coronavirus to infect people, after 229E, NL63, OC43, HKU1, MERS-CoV, and the original SARS-CoV. [105] Like the SARS-related coronavirus implicated in the 2003 SARS outbreak, SARS‑CoV‑2 is a member of the subgenus Sarbecovirus (beta-CoV lineage B). [106] [107] Coronaviruses undergo frequent recombination. [108]
M is a glycoprotein whose glycosylation varies according to coronavirus subgroup; N-linked glycosylation is typically found in the alpha and gamma groups while O-linked glycosylation is typically found in the beta group. [8] [9] There are some exceptions; for example, in SARS-CoV, a betacoronavirus, the M protein has one N-glycosylation site.
For this reason the spike protein has been the focus of development for COVID-19 vaccines in response to the COVID-19 pandemic caused by the virus SARS-CoV-2. [11] [12] A subgenus of the betacoronaviruses, known as embecoviruses (not including SARS-like coronaviruses), have an additional shorter surface protein known as hemagglutinin esterase. [13]
Spike (S) glycoprotein (sometimes also called spike protein, [2] formerly known as E2 [3]) is the largest of the four major structural proteins found in coronaviruses. [4] The spike protein assembles into trimers that form large structures, called spikes or peplomers, [3] that project from the surface of the virion.
The 3C-like protease inhibitor ensitrelvir received authorization to treat COVID-19 in Japan in 2022. [19] [20] In 2022, an ultralarge virtual screening campaign of 235 million molecules was able to identify a novel broad-spectrum inhibitor targeting the main protease of several coronaviruses. It is unusually not a peptidomimetic. [21]
The first cases of COVID-19 were confirmed in Indonesia on 2 March 2020, when two residents of Depok, West Java tested positive for the virus. [4] On 15 March, with 117 confirmed cases, President Joko Widodo had called for Indonesians to exercise social distancing measures, with some regional leaders in Jakarta, Banten and West Java had already closed down schools and places of gathering. [5]